Polynovo (ASX:PNV) announced its fiscal year’s total revenue, including contributions from BARDA, to be A$66.5 million, marking an impressive increase of 58.8% from the prior year.
The company foresees robust revenue growth in direct markets especially in the United States, United Kingdom, Australia, New Zealand, India, and Hong Kong for FY24.
Polynovo (ASX:PNV) is a leading company, developing unique biomedical devices using their patented NovoSorb biodegradable polymer technology.